代谢相关脂肪性肝病生活方式干预治疗进展

纪童童; 李鑫飞; 于岩岩; 徐小元; 徐京杭

doi:10.3969/j.issn.1001-5256.2023.08.004

代谢相关脂肪性肝病生活方式干预治疗进展

DOI: 10.3969/j.issn.1001-5256.2023.08.004

北京大学第一医院感染疾病科，北京 100034

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：纪童童、李鑫飞负责查找文献，撰写文稿；于岩岩、徐小元负责文章思路指导；徐京杭负责确定写作思路，指导文章撰写及最终定稿。纪童童和李鑫飞对本文贡献等同，为共同第一作者。

详细信息

通信作者:
徐京杭，ddcatjh@sina.com (ORCID: 0000-0001-8848-3876)

计量
- 文章访问数: 492
- HTML全文浏览量: 89
- PDF下载量: 131
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-04
- 录用日期: 2023-06-15
- 出版日期: 2023-08-20

Progress of lifestyle interventions for metabolic dysfunction-associated fatty liver disease

Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

More Information

Corresponding author: XU Jinghang, ddcatjh@sina.com (ORCID: 0000-0001-8848-3876)

摘要

摘要: 代谢相关脂肪性肝病(MAFLD)全球患病率高达25%~30%，MAFLD与肝硬化、肝细胞癌、肝外恶性肿瘤、糖尿病、心血管疾病的发病率和死亡率密切相关，带来了巨大的疾病负担。生活方式的改变，包括饮食和体育锻炼来实现减重，仍是现阶段MAFLD的一线治疗措施。本文拟综述生活方式干预治疗MAFLD的进展，旨在为MAFLD的治疗提供借鉴。
- 代谢相关脂肪性肝病 /
- 非酒精性脂肪性肝病 /
- 治疗学
Abstract: The global prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) is as high as 25%-30%. MAFLD is closely associated with the morbidity and mortality of liver cirrhosis, hepatocellular carcinoma, extrahepatic malignancies, diabetes mellitus, and cardiovascular diseases, resulting in substantial burden of diseases. Lifestyle interventions using diet and exercise to achieve weight loss remains a first-line therapy in patients with MAFLD. This article reviews the progress of lifestyle interventions for MAFLD to provide a reference for the treatment of this disease.
- Metabolic Dysfunction-Associated Fatty Liver Disease /
- Non-alcoholic Fatty Liver Disease /
- Therapeutics

HTML全文

参考文献(55)

[1]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[2]	NAN Y, AN J, BAO J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J]. J Hepatol, 2021, 75(2): 454-461. DOI: 10.1016/j.jhep.2021.05.003.
[3]	TARGHER G. Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data[J]. Liver Int, 2020, 40(11): 2879-2880. DOI: 10.1111/liv.14623.
[4]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[5]	RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835. DOI: 10.1097/HEP.0000000000000323.
[6]	ADAMS LA, ANSTEE QM, TILG H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J]. Gut, 2017, 66(6): 1138-1153. DOI: 10.1136/gutjnl-2017-313884.
[7]	ESLAM M, SARIN SK, WONG VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14(6): 889-919. DOI: 10.1007/s12072-020-10094-2.
[8]	ROMERO-GÓMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67(4): 829-846. DOI: 10.1016/j.jhep.2017.05.016.
[9]	XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007. 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
[10]	YE Q, ZOU B, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(8): 739-752. DOI: 10.1016/S2468-1253(20)30077-7.
[11]	DUELL PB, WELTY FK, MILLER M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association[J]. Arterioscler Thromb Vasc Biol, 2022, 42(6): e168-e185. DOI: 10.1161/ATV.0000000000000153.
[12]	YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
[13]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[14]	WANG X, WANG A, ZHANG R, et al. Associations between healthy lifestyle and all-cause mortality in individuals with metabolic associated fatty liver disease[J]. Nutrients, 2022, 14(20): 4222. DOI: 10.3390/nu14204222.
[15]	PROMRAT K, KLEINER DE, NIEMEIER HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis[J]. Hepatology, 2010, 51(1): 121-129. DOI: 10.1002/hep.23276.
[16]	VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLA-BERTOT L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149(2): 367-378. e5; quiz e14-15. DOI: 10.1053/j.gastro.2015.04.005.
[17]	YOUNOSSI ZM, COREY KE, LIM JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2021, 160(3): 912-918. DOI: 10.1053/j.gastro.2020.11.051.
[18]	MALESPIN MH, BARRITT AS 4th, WATKINS SE, et al. Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort[J]. Clin Gastroenterol Hepatol, 2022, 20(10): 2393-2395. e4. DOI: 10.1016/j.cgh.2021.01.023.
[19]	WONG VW, CHAN RS, WONG GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial[J]. J Hepatol, 2013, 59(3): 536-542. DOI: 10.1016/j.jhep.2013.04.013.
[20]	LONG MT, NOUREDDIN M, LIM JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review[J]. Gastroenterology, 2022, 163(3): 764-774. e1. DOI: 10.1053/j.gastro.2022.06.023.
[21]	HA J, YIM SY, KARAGOZIAN R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2022. DOI: 10.1016/j.cgh.2022.11.019. [Epub ahead of print].
[22]	ESLAM M, EL-SERAG HB, FRANCQUE S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(10): 638-651. DOI: 10.1038/s41575-022-00635-5.
[23]	LAZARUS JV, MARK HE, ANSTEE QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1): 60-78. DOI: 10.1038/s41575-021-00523-4.
[24]	ABDELMALEK MF, SUZUKI A, GUY C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2010, 51(6): 1961-1971. DOI: 10.1002/hep.23535.
[25]	SAAB S, MALLAM D, COX GA 2nd, et al. Impact of coffee on liver diseases: a systematic review[J]. Liver Int, 2014, 34(4): 495-504. DOI: 10.1111/liv.12304.
[26]	KOSITAMONGKOL C, KANCHANASURAKIT S, AUTTAMALANG C, et al. Coffee consumption and non-alcoholic fatty liver disease: an umbrella review and a systematic review and meta-analysis[J]. Front Pharmacol, 2021, 12: 786596. DOI: 10.3389/fphar.2021.786596.
[27]	YASKOLKA MEIR A, RINOTT E, TSABAN G, et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial[J]. Gut, 2021, 70(11): 2085-2095. DOI: 10.1136/gutjnl-2020-323106.
[28]	HE K, GUO LL, TANG H, et al. A freshwater fish-based diet alleviates liver steatosis by modulating gut microbiota and metabolites: a clinical randomized controlled trial in Chinese participants with nonalcoholic fatty liver disease[J]. Am J Gastroenterol, 2022, 117(10): 1621-1631. DOI: 10.14309/ajg.0000000000001885.
[29]	HANSEN CD, GRAM-KAMPMANN EM, HANSEN JK, et al. Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease : a randomized controlled trial[J]. Ann Intern Med, 2023, 176(1): 10-21. DOI: 10.7326/M22-1787.
[30]	KOO BK, KIM D, JOO SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis[J]. J Hepatol, 2017, 66(1): 123-131. DOI: 10.1016/j.jhep.2016.08.019.
[31]	PETTA S, CIMINNISI S, di MARCO V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2017, 45(4): 510-518. DOI: 10.1111/apt.13889.
[32]	EL SHERIF O, DHALIWAL A, NEWSOME PN, et al. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(3): 197-205. DOI: 10.1080/17474124.2020.1731303.
[33]	LAI JC, TANDON P, BERNAL W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the american association for the study of liver diseases[J]. Hepatology, 2021, 74(3): 1611-1644. DOI: 10.1002/hep.32049.
[34]	WANG J, QI Y, XIN Z, et al. Isotemporal substitution of different behaviour patterns with the presence of MAFLD in Chinese adults[J]. Liver Int, 2022, 42(12): 2683-2695. DOI: 10.1111/liv.15439.
[35]	MCPHERSON S, ARMSTRONG MJ, COBBOLD JF, et al. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group[J]. Lancet Gastroenterol Hepatol, 2022, 7(8): 755-769. DOI: 10.1016/S2468-1253(22)00061-9.
[36]	STINE JG, DIJOSEPH K, PATTISON Z, et al. Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Am J Gastroenterol, 2022. DOI: 10.14309/ajg.0000000000002098. [Epub ahead of print].
[37]	OH S, SO R, SHIDA T, et al. High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease[J]. Sci Rep, 2017, 7: 43029. DOI: 10.1038/srep43029.
[38]	KIM D, KONYN P, CHOLANKERIL G, et al. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by FibroScan[J]. Clin Gastroenterol Hepatol, 2022, 20(6): e1438-e1455. DOI: 10.1016/j.cgh.2021.06.029.
[39]	BERZIGOTTI A, ALBILLOS A, VILLANUEVA C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study[J]. Hepatology, 2017, 65(4): 1293-1305. DOI: 10.1002/hep.28992.
[40]	STINE JG, SCHREIBMAN IR, FAUST AJ, et al. NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH[J]. Hepatology, 2022, 76(1): 172-185. DOI: 10.1002/hep.32274.
[41]	KIM D, MURAG S, CHOLANKERIL G, et al. Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2021, 19(6): 1240-1247. e5. DOI: 10.1016/j.cgh.2020.07.023.
[42]	SIMON TG, KIM MN, LUO X, et al. Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts[J]. J Hepatol, 2020, 72(6): 1062-1069. DOI: 10.1016/j.jhep.2019.12.022.
[43]	HASHIDA R, KAWAGUCHI T, BEKKI M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review[J]. J Hepatol, 2017, 66(1): 142-152. DOI: 10.1016/j.jhep.2016.08.023.
[44]	GOLABI P, LOCKLEAR CT, AUSTIN P, et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review[J]. World J Gastroenterol, 2016, 22(27): 6318-6327. DOI: 10.3748/wjg.v22.i27.6318.
[45]	KATSAGONI CN, PAPATHEODORIDIS GV, IOANNIDOU P, et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial[J]. Br J Nutr, 2018, 120(2): 164-175. DOI: 10.1017/S000711451800137X.
[46]	EZPELETA M, GABEL K, CIENFUEGOS S, et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial[J]. Cell Metab, 2023, 35(1): 56-70. e3. DOI: 10.1016/j.cmet.2022.12.001.
[47]	ECKARD C, COLE R, LOCKWOOD J, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial[J]. Therap Adv Gastroenterol, 2013, 6(4): 249-259. DOI: 10.1177/1756283X13484078.
[48]	LAI SW. Smoking and nonalcoholic fatty liver disease[J]. Am J Gastroenterol, 2019, 114(6): 998.
[49]	ÅBERG F, FÄRKKILÄ M. Drinking and obesity: alcoholic liver disease/nonalcoholic fatty liver disease interactions[J]. Semin Liver Dis, 2020, 40(2): 154-162. DOI: 10.1055/s-0040-1701443.
[50]	ÅBERG F, PUUKKA P, SALOMAA V, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts[J]. Hepatology, 2020, 71(3): 835-848. DOI: 10.1002/hep.30864.
[51]	LIM SL, JOHAL J, ONG KW, et al. Lifestyle intervention enabled by mobile technology on weight loss in patients with nonalcoholic fatty liver disease: randomized controlled trial[J]. JMIR Mhealth Uhealth, 2020, 8(4): e14802. DOI: 10.2196/14802.
[52]	MAZZOTTI A, CALETTI MT, BRODOSI L, et al. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers[J]. J Hepatol, 2018, 69(5): 1155-1163. DOI: 10.1016/j.jhep.2018.07.013.
[53]	STINE JG, RIVAS G, HUMMER B, et al. Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH[J]. Hepatol Commun, 2023, 7(4): e0052. DOI: 10.1097/HC9.0000000000000052.
[54]	PFIRRMANN D, HUBER Y, SCHATTENBERG JM, et al. Web-based exercise as an effective complementary treatment for patients with nonalcoholic fatty liver disease: intervention study[J]. J Med Internet Res, 2019, 21(1): e11250. DOI: 10.2196/11250.
[55]	KWOK R, CHOI KC, WONG GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study[J]. Gut, 2016, 65(8): 1359-1368. DOI: 10.1136/gutjnl-2015-309265.